DAC: Davos Alzheimer's Collaborative Study: Sequential Administration of Digital Testing To Screen For Cognitive Impairment Followed By Blood Based Biomarkers To Assist With Timely Detection And Accurate Diagnosis Of Alzheimer's Disease
Study Details
Study Description
Brief Summary
The purpose of this study is to investigate how we can detect Alzheimer's disease early by using an online memory test and a simple blood test. These new methods for early diagnosis could allow people to begin treatment sooner, with the potential to improve the lives of millions of people.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| General study participants (patients)
|
Other: Cognitive Assessment
Montreal Cognitive Assessment - MoCA, which is a cognitive screening tool that assesses: memory, concentration, language, and orientation to time and place. this written cognitive test should take no more than 20 minutes.
Other Names:
|
| Healthcare Practitioners
|
|
| Pre-Program Chart Audits (100 patients what will be chart audited)
|
Outcome Measures
Primary Outcome Measures
- Quantify the proportion of individuals at least 65 years old with cognitive impairment [Less than 6 months]
Eligibility Criteria
Criteria
Inclusion Criteria
Subjects must meet the following criteria for entry into the study:
-
Male or female > 65 years of age at the time of consent;
-
Understand and voluntarily sign an informed consent form;
Inclusion criteria is assessed at both e-consent (assessed by participant's self-reporting of age and understanding) and in-person consent at TRI (assessed by clinical research coordinators in TRI).
Exclusion Criteria
Subjects who meet any of the following criteria will not be eligible for entry into the study:
-
Subjects who are unable to hear and see well enough to complete the assessments;
-
Prior diagnosis of dementia or Alzheimer's disease documented in their medical record and/or as diagnosed by a physician; Exclusion criteria is assessed by by participant's self-reporting of understanding and not having a prior diagnosis of dementia at the time of e-consentand visit 1 at TRI. ).
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | AdventHealth Translational Research Institute | Orlando | Florida | United States | 32804 |
Sponsors and Collaborators
- AdventHealth Translational Research Institute
- Davos Alzheimer's Collaborative
Investigators
- Principal Investigator: Steven Smith, MD, Study PI
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.- 1811673